Insider Selling: Twist Bioscience Co. (NASDAQ:TWST) CFO Sells 936 Shares of Stock

Twist Bioscience Co. (NASDAQ:TWST - Get Free Report) CFO Adam Laponis sold 936 shares of the business's stock in a transaction that occurred on Wednesday, May 21st. The shares were sold at an average price of $29.75, for a total value of $27,846.00. Following the completion of the sale, the chief financial officer now directly owns 106,018 shares in the company, valued at approximately $3,154,035.50. The trade was a 0.88% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Twist Bioscience Stock Performance

Shares of NASDAQ:TWST traded down $1.08 on Wednesday, reaching $28.33. 1,142,745 shares of the company's stock were exchanged, compared to its average volume of 978,754. The company has a quick ratio of 4.62, a current ratio of 4.96 and a debt-to-equity ratio of 0.03. The business's 50-day moving average is $35.90 and its two-hundred day moving average is $42.50. Twist Bioscience Co. has a fifty-two week low of $27.12 and a fifty-two week high of $60.90. The firm has a market capitalization of $1.70 billion, a price-to-earnings ratio of -8.38 and a beta of 2.54.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last posted its quarterly earnings data on Monday, May 5th. The company reported ($0.66) earnings per share for the quarter, missing the consensus estimate of ($0.56) by ($0.10). The company had revenue of $92.79 million during the quarter, compared to analyst estimates of $92.00 million. Twist Bioscience had a negative return on equity of 32.69% and a negative net margin of 59.76%. As a group, equities research analysts forecast that Twist Bioscience Co. will post -2.12 EPS for the current year.

Hedge Funds Weigh In On Twist Bioscience

Institutional investors have recently bought and sold shares of the stock. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in shares of Twist Bioscience by 186.1% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,442,262 shares of the company's stock worth $95,883,000 after acquiring an additional 1,588,587 shares during the last quarter. First Light Asset Management LLC bought a new stake in Twist Bioscience during the 4th quarter valued at approximately $56,984,000. EdgePoint Investment Group Inc. bought a new position in shares of Twist Bioscience during the 1st quarter worth about $43,705,000. Marshall Wace LLP increased its position in shares of Twist Bioscience by 15,927.8% during the fourth quarter. Marshall Wace LLP now owns 846,107 shares of the company's stock valued at $39,319,000 after purchasing an additional 840,828 shares during the period. Finally, Nuveen LLC bought a new stake in Twist Bioscience in the 1st quarter valued at $31,960,000.

Wall Street Analyst Weigh In

A number of research firms have recently commented on TWST. Barclays dropped their price objective on Twist Bioscience from $58.00 to $45.00 and set an "overweight" rating on the stock in a report on Thursday, April 10th. JPMorgan Chase & Co. dropped their price target on Twist Bioscience from $40.00 to $33.00 and set an "underweight" rating on the stock in a research report on Tuesday, May 6th. Robert W. Baird cut their price objective on shares of Twist Bioscience from $54.00 to $44.00 and set an "outperform" rating for the company in a research report on Tuesday, May 6th. The Goldman Sachs Group reduced their price target on Twist Bioscience from $55.00 to $48.00 and set a "buy" rating for the company in a report on Tuesday, May 6th. Finally, Guggenheim reiterated a "buy" rating and issued a $50.00 price objective on shares of Twist Bioscience in a research note on Tuesday, May 6th. One analyst has rated the stock with a sell rating, one has given a hold rating and eight have assigned a buy rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $50.40.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.